Sandwich ELISA using rabbit monoclonal antibodies for liver-stage malaria detection

Award Information
Agency: Department of Defense
Branch: Army
Contract: DAMD17-03-C-004
Agency Tracking Number: A022-0931
Amount: $69,888.00
Phase: Phase I
Program: SBIR
Awards Year: 2003
Solicitation Year: N/A
Solicitation Topic Code: N/A
Solicitation Number: N/A
Small Business Information
1015 Grandview Drive, South San Francisco, CA, 94080
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 Robert Pytela
 Chief Scientific Officer
 (650) 583-6688
Business Contact
 Guoliang Yu
Title: CEO
Phone: (650) 583-6688
Research Institution
Malaria is a major health problem worldwide, and its significance may be on the increase due to the rapid spread of parasite strains that are resistant to conventional anti-malaria drugs. Evidence suggests that during the inital phase of infection(liver-stage) the Plasmodium parasites may be susceptible to neutralization by drugs or vaccines. The infection of liver cells by plasmodium can be studied in vitro, using human hepatoma cell lines. This system could be used as a model to screen forneutralizing activity. However, this approach is hampered by the lack of a rapid quantitative assay for the number of plasmodium parasites that are present in a hepatoma cell culture. We propose to develop a novel sandwich ELISA assay that will facilitatethe rapid high-throughput screening of anti-malaria drugs. To this end, we will first raise novel rabbit monoclonal antibodies to several major proteins that are present in liver-stage plasmodium parasites. We will use our proprietary rabbit hybridomatechnology to develop antibodies to both synthetic peptides and recombinant proteins based on Plasmodium sequences. Pairs of antibodies recognizing independent epitopes on a given protein will be rapidly identified by using a novel sandwich screeningapproach. This research is designed to develop a rapid ELISA assay for quantifying malaria parasites present in infected liver cells. This novel assay will be substantailly more sensitive, specific, reliable, and easier to use than currently available assays. Itwill provide significant advantages to researchers developing novel approaches for the treatment of liver-stage malaria. On the basis of our novel assay, we will develop a test kit that will be marketed to research institutes, hospitals, and companiesinterested in quantifying infection by liver-stage plasmodium parasites. Furthermore, the novel monoclonal antibodies developed in the course of this project may have additional applications in malaria research and/or drug development.

* Information listed above is at the time of submission. *

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government